BG-C0979 / BeOne Medicines - LARVOL DELTA

First Quarter 2026 Business Highlights (Businesswire) - "Gastrointestinal Cancers - BGB-B2033 (GPC3x41BB bispecific antibody): Initiated potentially registrational study in patients with HCC. Received acceptance of Phase 1 study data as a rapid oral presentation at ASCO. Lung Cancer - BG-C0979 (ADAM9-targeting ADC): Initiated first-in-human study."

First-in-human • P1 data • Trial status • Hepatocellular Cancer • Solid Tumor

BG-C0979-101: A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors (clinicaltrialsregister.eu) - P1 | N=24 | Not yet recruiting | Sponsor: BeOne Medicines I GmbH

First-in-human • New P1 trial • Oncology • Solid Tumor

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: BeOne Medicines | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor